Ganesh N. Sharma, Deenanath Jhade and Bhushan Hatwar
The broad applicability of allergen-specific immunotherapy for the treatment and eventual prevention of Ig E - mediated allergy is limited by the poor quality and allergenic activity of natural allergen extracts that are used for the production of current allergy vaccines. Recombinant allergens equalling their natural counterparts have been produced for diagnosis and immunotherapy, and a large panel of genetically modified allergens with reduced allergenic activity has been characterized to improve safety of immunotherapy and explore allergen-specific prevention strategies. Recombinant allergens can be produced as defined molecules with consistent quality and unlimited amounts according to the corresponding DNA template. The recombinant allergen-based vaccination strategies will be generally applicable to most allergen sources, including respiratory, food and venom allergens and allow producing safe allergy vaccines for the treatment of the most common forms of IgE-mediated allergies.
English 
Spanish 
Chinese 
Russian 
German 
French 
Portuguese 
Hindi